Form: 8-K

Current report filing

November 4, 2021



apollomedintroa.jpg




Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, integration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's projected capitation and future liquidity, and may be identified by the use of forward-looking terms such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the U.S. Securities and Exchange Commission (the “SEC”), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q.

Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, you should not place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise.



footer.jpg
www.apollomed.net
2



Company Overview

Apollo Medical Holdings, Inc. (“ApolloMed”) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner.


companyoverviewa.jpg
footer.jpg
www.apollomed.net
3



Q3 Highlights

                                
strongfinancialresultsa.jpg
stellaracoa.jpg
strategictransactionsa.jpg
Strong financial results Stellar ACO performance in 2020 Strategic transactions
EPS (diluted)
$0.74
graphic1a.jpg 64% from $0.45
Generated $57.7M in gross savings, highest dollar amount out of all ACOs in the country
Closed the following transactions in Q3 2021:

• CAIPA MSO

• Access Primary Care Medical Group

•Sun Labs
Revenue
$227.1M
graphic1a.jpg 26% from $180.1M
Net income attr. to AMEH
$34.3M
graphic1a.jpg 105% from $16.7M
$21.8M impact on top line
Adj. EBITDA*
$74.5M
graphic1a.jpg 40% from $53.4M
$13.1M impact on bottom line
Signed agreement to purchase remaining 60% of equity interests in Diagnostic Medical Group of Southern California (DMG)
*See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” slides for more information.


footer.jpg
www.apollomed.net
4



Historical Financial Profile


historicalfinancialprofilea.jpg
footer.jpg
www.apollomed.net
5



Summary of Selected Financial Results

Three Months Ended September 30, Nine Months Ended September 30,
$ in 000s except per share data 2021 2020 2021 2020
Revenue
Capitation, net $ 149,059  $ 135,032  $ 438,350  $ 416,402 
Risk pool settlements and incentives 59,923  30,916  94,146  54,155 
Management fee income 9,652  8,707  26,345  26,212 
Fee-for-service, net 7,260  3,737  14,968  9,434 
Other income 1,223  1,731  5,006  4,194 
Total revenue 227,117  180,123  578,815  510,397 
Total expenses 173,957  142,767  482,884  455,770 
Income from operations 53,160 37,356 95,931 54,627
Net (loss) income (5,385) 25,424  68,603  109,412 
Net (loss) income attributable to noncontrolling interest (39,664) 8,711  8,515  81,603 
Net income attributable to ApolloMed $ 34,279 $ 16,713 $ 60,088 $ 27,809
Earnings per share - diluted $ 0.74 $ 0.45 $ 1.33 $ 0.75




footer.jpg
www.apollomed.net
6



Revenue Breakdown

revenuebreakdowna.jpg
footer.jpg
www.apollomed.net
7



Business Mix by Payer Type

YTD (Q1 - Q3) 2021
(% OF TOTAL REVENUE)
chart-4a12e6cee751458194a.jpg



footer.jpg
www.apollomed.net
8



Balance Sheet Highlights

$ in millions 9/30/2021 12/31/2020 $ Change % Change
Cash and cash equivalents and investments in marketable securities $333.3 $261.2 $72.2
graphic14.jpg
28%
Working capital $310.5 $223.6 $86.9
graphic14.jpg
39%
Total stockholders’ equity $440.3 $330.9 $109.4
graphic14.jpg
33%




footer.jpg
www.apollomed.net
9



Current Capitalization

(figures in millions, except per share price)
Recent Share Price (as of 11/1/2021) $ 70.67
Common Shares Outstanding 55.5
Market Capitalization $ 3,922.2
Plus: Total Bank Debt 187.5
Less: Cash and Cash Equivalents (1)
(145.7)
Implied Enterprise Value $ 3,964.0
Notes: Letters of Credit Availability on Revolving Credit Facility $ 25.0

Note: Data is as of 9/30/2021 unless otherwise stated.
(1) Excludes restricted cash of $59.1M



footer.jpg
www.apollomed.net
10



Updated 2021 Guidance

$ in millions, except per share information  2021 Guidance Range
(as of August 5, 2021)
 2021 Guidance Range
(as of November 4, 2021)
Total Revenue $700 - $720 $751.5 - $758.5
Net Income(1)
$56 - $66 $81 - $83.5
Net Income Attributable to ApolloMed $48 - $58 $71.5 - $73.5
Earnings per share - Diluted(2)
$1.58 - $1.62
EBITDA(3)
$100 - $119 $139 - $143
Adjusted EBITDA(3)
$120.5 - $130.5 $168.5 - $170.5

(1) Updated net income and EBITDA forecast is a result of APC’s investment in a payor partner that completed an initial public offering and became publicly traded on June 24, 2021. The revised net income and EBITDA guidance ranges assume the payor partner’s stock price of $8.49.

(2) Range was not previously provided as of August 5, 2021.

(3) See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” on slide 2.


footer.jpg
www.apollomed.net
11



Reconciliation of Net Income to EBITDA and Adjusted EBITDA

Three Months Ended September 30, Nine Months Ended September 30,
($ in millions) 2021 2020 2021 2020
Net (loss) income $ (5.4) $ 25.4  $ 68.6  $ 109.4 
Interest expense 1.0  2.5  4.3  8.0 
Interest income (0.4) (0.8) (1.3) (2.5)
(Benefit from) provision for income taxes (0.1) 10.8  31.6  44.2 
Depreciation and amortization 4.7  4.7  13.1  14.0 
EBITDA(1)
$ (0.3) $ 42.6  $ 116.3  $ 173.1 
(Income) loss from equity method investments $ (0.1) $ (0.4) $ 3.7  $ (3.3)
Gain on sale of equity method investment (2.2) —  (2.2) (99.6)
Other (income) expense (0.5) (0.1) 14.1  (1.5)
Unrealized loss (gain) on investments 60.9  —  (22.8) — 
Provider bonus payments 8.7  6.5  8.7  8.5 
Net loss adjustment for recently acquired IPAs 7.9  4.8  16.6  13.7 
Adjusted EBITDA(1)
$ 74.5  $ 53.4  $ 134.4  $ 90.8 

(1) See “Use of Non-GAAP Financial Measures” slide for more information.


footer.jpg
www.apollomed.net
12



Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA


2021 Guidance Range
(as of August 5, 2021)
2021 Guidance Range
(as of November 4, 2021)
($ in millions) Low High Low High
Net income $ 56.0  $ 66.0  $ 81.0  $ 83.5 
Interest expense 6.0  8.4  5.0  6.0 
Interest income (1.5) (2.4) (1.2) (1.7)
Provision for income taxes 24.0  29.0  37.0  38.0 
Depreciation and amortization 15.5  18.0  17.2  17.2 
EBITDA $ 100.0  $ 119.0  $ 139.0  $ 143.0 
Loss (income) from equity method investments $ 3.5  $ (0.5) $ (3.9) $ (3.6)
Investment in payor partner (9.0) (9.0) —  — 
Provider bonus payments 6.0  6.0  8.9  8.9 
Net loss adjustment for recently acquired IPAs 20.0  15.0  24.5  22.2 
Adjusted EBITDA $ 120.5  $ 130.5  $ 168.5  $ 170.5 




footer.jpg
www.apollomed.net
13



Use of Non-GAAP Financial Measures


This presentation contains the non-GAAP financial measures Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with GAAP is net (loss) income. These measures are not in accordance with, or are an alternative to, U.S. generally accepted accounting principles (“GAAP”), and may be different from other non-GAAP financial measures used by other companies. ApolloMed uses Adjusted EBITDA as a supplemental performance measure of its operations,  for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding losses from equity method investments provide bonus payments, impairment of intangibles, provision of doubtful accounts and other income earned that is not related to ApolloMed's normal operations. Adjusted EBITDA also excludes non recurring items, including the effect on EBITDA of certain recently acquired IPAs.

ApolloMed believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information as they allow investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core and non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ApolloMed's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators ApolloMed uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, ApolloMed has provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided above.




footer.jpg
www.apollomed.net
14




Key Acronyms

ACO: Accountable Care Organization
AIPBP: All-Inclusive Population-Based Payments
CMMI: Center for Medicare and Medicaid Innovation
CMS: Centers for Medicare & Medicaid Services
DME: Durable Medical Equipment
Health Plan/Payors: Health Insurance Companies
HMO: Health Maintenance Organization
IPA: Independent Practice Association
NCI: Non-Controlling Interest







NMM: Network Medical Management, Inc.
MSA: Master Service Agreement
MSO: Management Services Organization
NGACO: Next Generation Accountable Care Organization
PCP: Primary Care Physician
PMPM: Per Member Per Month
SNF: Skilled Nursing Facility
VIE: Variable Interest Entity







footer.jpg
www.apollomed.net
15



apollomedendpagea.jpg